Quest Diagnostics is the world's leading provider of diagnostic testing information services. We provide insights that empower and enable patients, physicians, hospitals, integrated delivery networks health plans, employers and others to make better healthcare decisions. We conduct business through our headquarters in Secaucus, New Jersey, and our laboratories, patient service centers, offices and other facilities around the United States and in selected locations outside the United States. Our vision is: empowering better health with diagnostic insights. We have three aspirational goals: a healthier world; build a valuable company; and create an inspiring workplace.
Due to increased awareness of violence and human rights violations in the Democratic Republic of Congo and the adjoining countries and its relationship to the mining of certain minerals (specifically tin, tantalum, tungsten and gold), on August 22, 2012, the final rule regarding sourcing of conflict minerals under Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act (“the Dodd-Frank Act”) was approved by the U.S. Securities and Exchange Commission (SEC). Section 1502 added Section 13(p) to the Securities Exchange Act of 1934, requiring publicly traded companies subject to the SEC to report annually on whether any of the minerals originated in the Democratic Republic of Congo or an adjoining country.
Our policy and efforts
Quest Diagnostics has initiated a comprehensive process to comply with Dodd Frank Section 1502, including supply chain due diligence measures and internal controls. Pursuant to this policy, Quest Diagnostics is specifically:
- Using the OECD Due Diligence Guidance as the international framework for meeting the sourcing expectations of our customers, regulators and stakeholders.
- Strengthening its due diligence capabilities and processes to help identify the source of any conflict minerals that may be present in company products.
- Committed to improving over time our ability to track and trace conflict minerals that may be identified in our supply chain. Our expectations of suppliers include a timely response to our queries about purchased components, assistance in reaching out to their suppliers in case the source of minerals is unknown and regular communications with Quest Diagnostics about our suppliers’ conflict minerals tracking and tracing efforts.
- For further information, questions or to report any issues regarding the Quest Diagnostics conflict mineral program, please call: 973-520-2900 (our investor relations line), or contact the Quest Diagnostics Legal Department by calling 973-520-2700.
This policy will be regularly reviewed and updated.
Applying our policy
After an analysis of our products and applying our policy in respect of the 2013 reporting period, we filed a Specialized Disclosure Report on Form SD and an associated Conflict Minerals Report with the Securities and Exchange Commission, reporting the results of our efforts.
Our business has continued to evolve. After an analysis of our products and applying our policy in respect of the 2019, 2020 and 2021 reporting periods, we concluded that conflict minerals were not necessary to the functionality or production of any product that Quest Diagnostics and its subsidiaries manufactured or contracted to manufacture during those reporting periods. Consequently, we were not obligated to, and did not, file a Specialized Disclosure Report on Form SD or an associated Conflict Minerals Report with the Securities and Exchange Commission in respect of 2019, 2020 or 2021.